BioLineRx raises $3.75M in registered direct offering and private placement

What's the deal? BioLineRx, a clinical-stage biopharmaceutical company in oncology and rare diseases, has agreed to raise $3.75 million through a registered direct offering and a concurrent private placement. The Tel Aviv-based company will sell 1,348,921 American Depositary Shares (ADSs) at $2.78 each, with accompanying warrants to purchase up to 2,023,382 ADSs. ChardanDealroom has a profile for this one. Try Dealroom → is acting as exclusive placement agent, and closing is expected on or about August 31, 2026.

The details: The warrants carry an exercise price of $2.78 per ADS and expire five years from issuance. Each ADS represents 600 ordinary shares. The $3.75 million figure is gross, before placement agent fees and other expenses.

What's the endgame? BioLineRx intends to use the net proceeds for research and development, working capital, and general corporate purposes.

Why now? Alongside the offering, the company amended outstanding warratns held by the participating investor. Effective at closing, warrants to purchase 277,273 ADSs will see their exercise price cut to $2.78 and their expiration extended to August 31, 2031.

The signal: The small, dilutive raise — priced at market and paired with heavy warrant coverage — points to a clinical-stage biotech leaning on capital markets to fund its pipeline. Reworking existing warrant terms to sweeten the deal underscores how tight financing conditions have become for smaller drug developers.

Image credit: Generated with Gemini